Ernexa Therapeutics (ERNAW) Total Liabilities (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Total Liabilities data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Total Liabilities fell 66.54% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 66.54% YoY) and the FY2025 annual result came in at $3.4 million, down 3.78% from the prior year.
• Total Liabilities climbed to $3.7 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $55.0 million in Q2 2024 to a low of $2.6 million in Q3 2025.
• A 5-year average of $22.8 million and a median of $12.1 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 586.71% — and 2025, when it plunged 95.1%.
• Tracing ERNAW's Total Liabilities over 5 years: stood at $10.2 million in 2022, then jumped by 361.06% to $46.9 million in 2023, then plunged by 92.39% to $3.6 million in 2024, then slipped by 3.78% to $3.4 million in 2025, then climbed by 7.31% to $3.7 million in 2026.
• The last three Total Liabilities figures came in at $3.7 million (Q1 2026), $3.4 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.